April 2014 Edition Vol.11, Issue 4

A Revolution in Cancer Care: Cancer Immunotherapeutics in the Pipeline

A Revolution in Cancer Care: Cancer Immunotherapeutics in the Pipeline (Continued)

Bibliography

  1. Adaptimmune. 2014.
  2. Bristol-Myers Squibb. Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analysis of Yervoy® (ipilimumab) Treatment in More Than 1,800 Patients with Metastatic or Locally Advanced or Unresectable Melanoma. 09/27/2013. <http://news.bms.com/press-release/rd-news/bristol-myers-squibb-announces-long-term-survival-results-pooled-analysis-yerv>
  3. Cancer.org. "Sipuleucel-T." 2014. <http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/sipuleucel-t>
  4. Couzin-Frankel, Jennifer. "Cancer Immunotherapy." Science Magazine 12/202013. <https://www.sciencemag.org/content/342/6165/1432.full>
  5. Creelan B "Update on Immune Checkpoint Inhibitors in Lung Cancer." Cancer control : Journal of the Moffitt Cancer Center 1 (2014): 80-9
  6. Dolgin, Elie. “Material breach: An experimental vaccine implanted beneath the skin could usher in biomaterial-based immunotherapies for cancer. Nature 504 (2013); S16-S17.
  7. FDA. "FDA Approval for Sipuleucel-T.” 2014.
  8. FDA. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer. 04/29/2010. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm>
  9. FDA. FDA Approves New Treatment for a Type of Late-stage Skin Cancer. 03/25/2011. <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm1193237.htm>
  10. Finn O "Immuno-oncology: Understanding the Function and Dysfunction of the Immune System in Cancer." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO (2012): viii6-9
  11. Hodi F, O'Day S, McDermott D, Weber R, Sosman J, Haanen J, Gonzalez R, Robert C, et al. "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma." The New England journal of medicine 8 (2010): 711-23
  12. Humphries C "Adoptive Cell Therapy: Honing That Killer Instinct." Nature 7480 (2013): S13-5
  13. Kantoff, P et.al. “Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.” N Engl J Med 2010; 363:411-422, July 29, 2010
  14. Lowry, Fran. "Nivolumab May 'Raise Expectations' in Metastatic Cancer, Say NCI Docs." Medscape Medical News. 03/04/2014. <http://www.medscape.com/viewarticle/821481>
  15. Merck. Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma. 04/24/2013. <http://www.mercknewsroom.com/press-release/research-and-development-news/merck-announces-breakthrough-therapy-designation-lambrol>
  16. Merck. Merck Announces Presentation of Interim Data from Phase 1B Study of MK-3475, Investigational Anti-PD-1 Immunotherapy, in Previously-Treated Patients with Non-Small Cell Lung Cancer (NSCLC) at 15th World Conference on Lung Cancer. 10/29/2013. <http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-presentation-interim-data-phase-1b-study->
  17. Merck. Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma. 11/11/2012. <http://www.mercknewsroom.com/press-release/research-and-development-news/merck-presents-early-stage-interim-data-mk-3475-investig>
  18. Novartis. Novartis Expands Cancer Immunotherapy Research Program with Acquisition of CoStim. 02/17/2014.
  19. Pardoll D "The Blockade of Immune Checkpoints in Cancer Immunotherapy." Nature reviews. Cancer 4 (2012): 252-64
  20. Roche. Roche Presents Updated Data on Investigational Cancer Immunotherapy MPDL3280A (anti-PDL1) in Lung Cancer at ECC 2013. 09/29/2013. <http://www.roche.com/investors/ir_update/inv-update-2013-09-29.htm>
  21. Rosenberg S, Yang J, Sherry R, Kammula U, Hughes M, Phan G, Citrin D, Restifo N, et al. "Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-cell Transfer Immunotherapy." Clinical cancer research : an official journal of the American Association for Cancer Research 13 (2011): 4550-7
  22. Topalian S, Sznol M, McDermott D, Kluger H, Carvajal R, Sharfman W, Brahmer J, Lawrence D, et al. "Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab." Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014):

Pages: 1 2 3

Post a Comment

OBR Archives

To view previous issues of OBR green you can visit our archives. The entire library of OBR green articles is searchable.